268 related articles for article (PubMed ID: 26943851)
1. Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study.
Franceschi E; Depenni R; Paccapelo A; Ermani M; Faedi M; Sturiale C; Michiara M; Servadei F; Pavesi G; Urbini B; Pisanello A; Crisi G; Cavallo MA; Dazzi C; Biasini C; Bertolini F; Mucciarini C; Pasini G; Baruzzi A; Brandes AA;
J Neurooncol; 2016 May; 128(1):157-162. PubMed ID: 26943851
[TBL] [Abstract][Full Text] [Related]
2. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.
Minniti G; Salvati M; Arcella A; Buttarelli F; D'Elia A; Lanzetta G; Esposito V; Scarpino S; Maurizi Enrici R; Giangaspero F
J Neurooncol; 2011 Apr; 102(2):311-6. PubMed ID: 20686820
[TBL] [Abstract][Full Text] [Related]
3. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
[TBL] [Abstract][Full Text] [Related]
4. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
[TBL] [Abstract][Full Text] [Related]
5. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN
J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762
[TBL] [Abstract][Full Text] [Related]
7. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status.
Brandes AA; Tosoni A; Franceschi E; Sotti G; Frezza G; Amistà P; Morandi L; Spagnolli F; Ermani M
J Clin Oncol; 2009 Mar; 27(8):1275-9. PubMed ID: 19188675
[TBL] [Abstract][Full Text] [Related]
8. Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide.
Thon N; Eigenbrod S; Grasbon-Frodl EM; Lutz J; Kreth S; Popperl G; Belka C; Kretzschmar HA; Tonn JC; Kreth FW
J Neurol Neurosurg Psychiatry; 2011 Apr; 82(4):441-6. PubMed ID: 20861061
[TBL] [Abstract][Full Text] [Related]
9. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
Carlson BL; Grogan PT; Mladek AC; Schroeder MA; Kitange GJ; Decker PA; Giannini C; Wu W; Ballman KA; James CD; Sarkaria JN
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):212-9. PubMed ID: 19695438
[TBL] [Abstract][Full Text] [Related]
10. Treatment options and outcomes for glioblastoma in the elderly patient.
Arvold ND; Reardon DA
Clin Interv Aging; 2014; 9():357-67. PubMed ID: 24591820
[TBL] [Abstract][Full Text] [Related]
11. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
Weiler M; Hartmann C; Wiewrodt D; Herrlinger U; Gorlia T; Bähr O; Meyermann R; Bamberg M; Tatagiba M; von Deimling A; Weller M; Wick W
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):670-6. PubMed ID: 19836157
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
Brandes AA; Franceschi E; Tosoni A; Benevento F; Scopece L; Mazzocchi V; Bacci A; Agati R; Calbucci F; Ermani M
Cancer; 2009 Aug; 115(15):3512-8. PubMed ID: 19514084
[TBL] [Abstract][Full Text] [Related]
13. Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.
Minniti G; Armosini V; Salvati M; Lanzetta G; Caporello P; Mei M; Osti MF; Maurizi RE
J Neurooncol; 2011 Jul; 103(3):683-91. PubMed ID: 21052773
[TBL] [Abstract][Full Text] [Related]
14. MGMT gene promoter methylation in pediatric glioblastomas.
Srivastava A; Jain A; Jha P; Suri V; Sharma MC; Mallick S; Puri T; Gupta DK; Gupta A; Sarkar C
Childs Nerv Syst; 2010 Nov; 26(11):1613-8. PubMed ID: 20585787
[TBL] [Abstract][Full Text] [Related]
15. The Impact of
Jovanović N; Mitrović T; Cvetković VJ; Tošić S; Vitorović J; Stamenković S; Nikolov V; Kostić A; Vidović N; Krstić M; Jevtović-Stoimenov T; Pavlović D
Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30717206
[No Abstract] [Full Text] [Related]
16. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.
Mirimanoff RO; Gorlia T; Mason W; Van den Bent MJ; Kortmann RD; Fisher B; Reni M; Brandes AA; Curschmann J; Villa S; Cairncross G; Allgeier A; Lacombe D; Stupp R
J Clin Oncol; 2006 Jun; 24(16):2563-9. PubMed ID: 16735709
[TBL] [Abstract][Full Text] [Related]
17. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial.
Grossman SA; Ye X; Chamberlain M; Mikkelsen T; Batchelor T; Desideri S; Piantadosi S; Fisher J; Fine HA
J Clin Oncol; 2009 Sep; 27(25):4155-61. PubMed ID: 19636006
[TBL] [Abstract][Full Text] [Related]
18. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
Minniti G; Amelio D; Amichetti M; Salvati M; Muni R; Bozzao A; Lanzetta G; Scarpino S; Arcella A; Enrici RM
Radiother Oncol; 2010 Dec; 97(3):377-81. PubMed ID: 20855119
[TBL] [Abstract][Full Text] [Related]
19. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma.
Kocher M; Frommolt P; Borberg SK; Rühl U; Steingräber M; Niewald M; Staar S; Stuschke M; Becker G; Fischedick AR; Herfarth K; Grauthoff H; Müller RP
Strahlenther Onkol; 2008 Nov; 184(11):572-9. PubMed ID: 19016015
[TBL] [Abstract][Full Text] [Related]
20. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
Gupta SK; Kizilbash SH; Carlson BL; Mladek AC; Boakye-Agyeman F; Bakken KK; Pokorny JL; Schroeder MA; Decker PA; Cen L; Eckel-Passow JE; Sarkar G; Ballman KV; Reid JM; Jenkins RB; Verhaak RG; Sulman EP; Kitange GJ; Sarkaria JN
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26615020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
